Author

Rebecca Sheets

Observed names: R L Sheets, R Sheets, R. Sheets, R.A. Sheets, REBECCA L. SHEETS, Rebecca L Sheets, Rebecca L. Sheets, Rebecca Lynn Sheets, Sheets, Rebecca L.

Observed institutions: University of Southern California, National Institutes of Health, International Vaccine Institute, Center for Biologics Evaluation and Research, United States Food and Drug Administration, University of Utah, United States Public Health Service, International Alliance for Biological Standardization, National Institute of Allergy and Infectious Diseases, Vaccine Research Center, Catholic University of America

ORCID: 0000-0001-5662-2763

Observed ORCID: 0000-0001-5662-2763

OpenAlex ID: A5058328769

Nucleotide Sequence of Yellow Fever Virus: Implications for Flavivirus Gene Expression and Evolution

1985 · Charles M. Rice, Edith M. Lenches, et al. · Science · 961

Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus Vector

2006 · Andrew T. Catanzaro, Richard A. Koup, et al. · The Journal of Infectious Diseases · 321

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

2010 · J.E. Ledgerwood, P. Costner, et al. · Vaccine · 210

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial

2014 · U. N. Sarwar, P. Costner, et al. · The Journal of Infectious Diseases · 131

PDF

Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts

2006 · Rebecca L. Sheets, Judith Stein, et al. · Toxicological Sciences · 107

PDF

Mobile elements bounded by C4A4 telomeric repeats in oxytricha fallax

1985 · Glenn Herrick, Samuel Cartinhour, et al. · Cell · 102

PDF

Mechanism of Ad5 Vaccine Immunity and Toxicity: Fiber Shaft Targeting of Dendritic Cells

2007 · Cheng Cheng, Jason G. D Gall, et al. · PLoS Pathogens · 83

PDF

Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products

2014 · James Gombold, Stephen Karakasidis, et al. · Vaccine · 70

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)

2015 · Jonathan D. Fuchs, Ian Frank, et al. · Open Forum Infectious Diseases · 67

PDF

Recombinant feline leukemia virus genes detected in naturally occurring feline lymphosarcomas

1993 · R L Sheets, R Pandey, et al. · Journal of Virology · 67

PDF

Mode of action of adjuvants: Implications for vaccine safety and design

2010 · Béatris Mastelic, Sohail Ahmed, et al. · Biologicals · 66

Biodistribution and Toxicological Safety of Adenovirus Type 5 and Type 35 Vectored Vaccines Against Human Immunodeficiency Virus-1 (HIV-1), Ebola, or Marburg Are Similar Despite Differing Adenovirus Serotype Vector, Manufacturer's Construct, or Gene Inserts

2008 · Rebecca L. Sheets, Judith Stein, et al. · Journal of Immunotoxicology · 57

PDF

Adventitious agents in viral vaccines: Lessons learned from 4 case studies

2014 · John Petricciani, Rebecca Sheets, et al. · Biologicals · 56

Evaluation of the human host range of bovine and porcine viruses that may contaminate bovine serum and porcine trypsin used in the manufacture of biological products

2011 · Carol Marcus-Sekura, James C. Richardson, et al. · Biologicals · 55

Toxicological Safety Evaluation of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar Despite Differing Plasmid Backbones or Gene-Inserts

2006 · Rebecca L. Sheets, Judith Stein, et al. · Toxicological Sciences · 54

PDF

Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains

2016 · Richard C. Condit, Anna-Lise Williamson, et al. · Vaccine · 47

Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations

2009 · I. Knezevic, G. Stacey, et al. · Biologicals · 46

Controlled Human Infection Models To Accelerate Vaccine Development

2022 · Robert K. M. Choy, A. Louis Bourgeois, et al. · Clinical Microbiology Reviews · 44

Inclusion of Adolescents in Preventive HIV Vaccine Trials

2008 · Heather B Jaspan, Coleen K Cunningham, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 42

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)

2014 · Robert T. Chen, Baevin Carbery, et al. · Vaccine · 36

PDF

Biologically selected recombinants between Feline Leukemia Virus (FeLV) subgroup a and an endogenous FeLV element

1992 · Rebecca Lynn Sheets, Rakesh Pandey, et al. · Virology · 35

WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20–22 April 2021

2022 · Margaret A. Liu, Tiequn Zhou, et al. · Emerging Microbes & Infections · 33

PDF

Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis

2016 · Bettina Klug, James S. Robertson, et al. · Vaccine · 27

An overview of animal cell substrates for biological products

2008 · John Petricciani, Rebecca Sheets · Biologicals · 27

Review of efficacy trials of HIV-1/AIDS vaccines and regulatory lessons learned

2015 · Rebecca L. Sheets, TieQun Zhou, et al. · Biologicals · 23

PDF

Works count: 82

Citation count: 2,934

H-index: 24

I10-index: 32